DK3368069T3 - Anvendelse af myostatininhibitorer og kombinationsterapier - Google Patents

Anvendelse af myostatininhibitorer og kombinationsterapier Download PDF

Info

Publication number: DK3368069T3
Authority: DK; Denmark
Prior art keywords: myostatini; inhibitors; combination therapies; therapies; combination
Prior art date: 2016-06-13

Application number

DK17732001.7T

Other languages

English (en)

Inventor

Kimberly Long

Adriana Donovan

Yung Chyung

Michelle Straub

Original Assignee

Scholar Rock Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-13

Filing date

2017-06-13

Publication date

2020-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59093642&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3368069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-06-13 Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc

2020-11-02 Application granted granted Critical

2020-11-02 Publication of DK3368069T3 publication Critical patent/DK3368069T3/da

Links

238000002648 combination therapy Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

DK17732001.7T 2016-06-13 2017-06-13 Anvendelse af myostatininhibitorer og kombinationsterapier DK3368069T3 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201662349596P	2016-06-13	2016-06-13
US201762470157P	2017-03-10	2017-03-10
US201762486934P	2017-04-18	2017-04-18
US201762511702P	2017-05-26	2017-05-26
US201762512254P	2017-05-30	2017-05-30
PCT/US2017/037332 WO2017218592A1 (en)	2016-06-13	2017-06-13	Use of myostatin inhibitors and combination therapies

Publications (1)

Publication Number	Publication Date
DK3368069T3 true DK3368069T3 (da)	2020-11-02

Family

ID=59093642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17732001.7T DK3368069T3 (da)	2016-06-13	2017-06-13	Anvendelse af myostatininhibitorer og kombinationsterapier

Country Status (19)

Country	Link
US (2)	US10946036B2 (da)
EP (3)	EP3368069B1 (da)
JP (4)	JP6823167B2 (da)
KR (4)	KR20230028813A (da)
AU (3)	AU2017283546C1 (da)
CL (1)	CL2018003588A1 (da)
CY (1)	CY1123678T1 (da)
DK (1)	DK3368069T3 (da)
ES (1)	ES2830440T3 (da)
HR (1)	HRP20201764T1 (da)
HU (1)	HUE051480T2 (da)
IL (2)	IL301468A (da)
LT (1)	LT3368069T (da)
MY (1)	MY185614A (da)
PE (1)	PE20190205A1 (da)
PT (1)	PT3368069T (da)
RS (1)	RS61090B1 (da)
SI (1)	SI3368069T1 (da)
WO (1)	WO2017218592A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007114319A1 (ja)	2006-03-31	2007-10-11	Chugai Seiyaku Kabushiki Kaisha	抗体の血中動態を制御する方法
JP5334319B2 (ja)	2007-09-26	2013-11-06	中外製薬株式会社	Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
PL2708558T3 (pl)	2008-04-11	2018-09-28	Chugai Seiyaku Kabushiki Kaisha	Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
WO2012073992A1 (ja)	2010-11-30	2012-06-07	中外製薬株式会社	複数分子の抗原に繰り返し結合する抗原結合分子
US11236168B2 (en)	2012-08-24	2022-02-01	Chugai Seiyaku Kabushiki Kaisha	Mouse FcγammaRII-specific Fc antibody
SG11201508170TA (en)	2013-04-02	2015-11-27	Chugai Pharmaceutical Co Ltd	Fc REGION VARIANT
EP3215175A4 (en)	2014-11-06	2018-06-27	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
PE20221834A1 (es)	2014-12-19	2022-11-29	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina
CA2974547A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
CA3036652A1 (en)	2015-09-15	2017-03-23	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
JP6823167B2 (ja)	2016-06-13	2021-01-27	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	ミオスタチン阻害剤の使用および併用療法
AU2017285764B2 (en) *	2016-06-17	2024-05-02	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies and methods of use
MX2019001448A (es)	2016-08-05	2019-09-13	Chugai Pharmaceutical Co Ltd	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018187209A1 (en) *	2017-04-03	2018-10-11	Acceleron Pharma Inc.	Compositions and methods for treating spinal muscular atrophy
KR102636384B1 (ko)	2017-08-04	2024-02-14	스카이호크 테라퓨틱스, 인코포레이티드	스플라이싱을 조절하는 방법 및 조성물
WO2019170930A1 (es) *	2018-03-09	2019-09-12	Universitat De Lleida	Tratamiento para la atrofia muscular espinal
EP3781214A4 (en) *	2018-04-17	2022-04-13	Applied StemCell, Inc.	COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
CR20210416A (es)	2019-01-30	2021-09-14	Scholar Rock Inc	INHIBIDORES ESPECIFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS
KR20210135241A (ko)	2019-02-05	2021-11-12	스카이호크 테라퓨틱스, 인코포레이티드	스플라이싱을 조절하는 방법 및 조성물
KR20210135507A (ko)	2019-02-06	2021-11-15	스카이호크 테라퓨틱스, 인코포레이티드	스플라이싱을 조절하는 방법 및 조성물
US11918570B2 (en)	2020-04-13	2024-03-05	The Research Foundation For The State University Of New York	Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
AU2021369471A1 (en)	2020-10-26	2023-06-15	Scholar Rock, Inc.	Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
AU2022299185A1 (en)	2021-06-23	2024-01-25	Scholar Rock, Inc.	A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023288277A1 (en)	2021-07-14	2023-01-19	Scholar Rock, Inc.	Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023057404A1 (en) *	2021-10-06	2023-04-13	F. Hoffmann-La Roche Ag	Novel combined administration
WO2023215384A2 (en) *	2022-05-04	2023-11-09	Scholar Rock, Inc.	Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
WO1993011236A1 (en)	1991-12-02	1993-06-10	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US7566768B1 (en)	1995-10-26	2009-07-28	The Johns Hopkins University School Of Medicine	Promyostatin peptides and methods of using same
DK0690873T3 (da)	1993-03-19	2003-09-29	Univ Johns Hopkins Med	Vækstdifferentieringsfaktor-8
US7393682B1 (en)	1993-03-19	2008-07-01	The Johns Hopkins University School Of Medicine	Polynucleotides encoding promyostatin polypeptides
US5994618A (en)	1997-02-05	1999-11-30	Johns Hopkins University School Of Medicine	Growth differentiation factor-8 transgenic mice
ATE305036T1 (de)	1994-07-08	2005-10-15	Univ Johns Hopkins Med	Wachstums-differenzierungsfaktor-11
US20030167492A1 (en)	1994-07-08	2003-09-04	Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6656475B1 (en)	1997-08-01	2003-12-02	The Johns Hopkins University School Of Medicine	Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
WO2002002641A1 (en)	2000-06-16	2002-01-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
AU2011244851A1 (en)	2000-07-27	2011-11-24	The John Hopkins University School Of Medicine	Promyostatin peptides and methods of using same
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
DE60128914T2 (de)	2001-10-05	2008-05-08	Affimed Therapeutics Ag	Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
US8455627B2 (en)	2001-10-05	2013-06-04	Affimed Therapeutics, Ag	Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
US20040044063A1 (en)	2002-05-31	2004-03-04	Brent Stockwell	SMA therapy and cell based assay for identifying therapies
CN102755646A (zh)	2002-07-19	2012-10-31	艾博特生物技术有限公司	TNF α相关疾病的治疗
JP4547561B2 (ja)	2002-09-16	2010-09-22	ザジョンズホプキンスユニバーシティー	メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
CN100434440C (zh)	2002-12-02	2008-11-19	阿布格尼克斯公司	针对肿瘤坏死因子的抗体及其用途
SG153874A1 (en)	2003-12-31	2009-07-29	Schering Plough Ltd	Neutralizing epitope-based growth enhancing vaccine
US7456149B2 (en)	2004-03-02	2008-11-25	Acceleron Pharma, Inc.	ALK7 and myostatin inhibitors and uses thereof
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
AU2005247508A1 (en)	2004-05-27	2005-12-08	Acceleron Pharma Inc.	Cerberus/coco derivatives and uses thereof
JP2008515774A (ja)	2004-08-03	2008-05-15	ダイアックスコーポレイション	ｈＫ１結合タンパク質
WO2006081139A2 (en)	2005-01-26	2006-08-03	Abgenix, Inc.	Antibodies against interleukin-1 beta
US20060216279A1 (en) *	2005-03-22	2006-09-28	Glass David J	Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
PE20061395A1 (es)	2005-04-25	2007-01-15	Amgen Fremont Inc	Anticuerpos contra miostatina
AU2006283725B2 (en)	2005-08-19	2012-02-16	The Trustees Of The University Of Pennsylvania	Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
UA92504C2 (en)	2005-10-12	2010-11-10	Эли Лилли Энд Компани	Anti-myostatin monoclonal antibody
WO2007061995A2 (en)	2005-11-21	2007-05-31	Novartis Ag	Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en)	2006-06-30	2012-01-17	Lakewood-Amedex, Inc.	Compositions and methods for the treatment of muscle wasting
WO2008030367A2 (en) *	2006-09-01	2008-03-13	The General Hospital Corporation	Selective myostatin inhibitors
EP2097095B1 (en)	2006-11-29	2016-01-27	Nationwide Children's Hospital	Myostatin inhibition for enhancing muscle and/or improving muscle function
EP2769731A1 (en)	2007-02-23	2014-08-27	The Trustees of Columbia University in the City of New York	Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
US8119026B2 (en)	2007-03-30	2012-02-21	Merck Patent Gesellschaft Mit Beschrankter Haftung	Birefringent layer with negative optical dispersion
US7935687B2 (en)	2007-04-12	2011-05-03	Paratek Pharmaceuticals, Inc.	Methods for treating spinal muscular atrophy using tetracycline compounds
WO2008150530A2 (en)	2007-06-01	2008-12-11	Biogen Idec Ma Inc.	Cripto binding molecules
TW200918553A (en)	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
PE20091163A1 (es)	2007-11-01	2009-08-09	Wyeth Corp	Anticuerpos para gdf8
AR074777A1 (es)	2008-12-19	2011-02-09	Glaxo Group Ltd	Proteinas de union a antigeno
WO2010099219A2 (en)	2009-02-24	2010-09-02	The Salk Institute For Biological Studies	Designer ligands of tgf-beta superfamily
CN104725512A (zh)	2009-04-27	2015-06-24	诺华股份有限公司	增加肌肉生长的组合物和方法
CN104840944A (zh)	2009-06-08	2015-08-19	阿塞勒隆制药公司	用于增加产热脂肪细胞的方法
MX340295B (es)	2010-03-10	2016-07-05	Genmab As	Anticuerpos monoclonales anti-c-met.
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
CN105440134A (zh)	2010-08-16	2016-03-30	安姆根公司	结合肌肉生长抑制素的抗体、组合物和方法
JP6268097B2 (ja)	2011-11-11	2018-01-24	デューク・ユニヴァーシティ	固形腫瘍治療のための併用薬物療法
US20130178454A1 (en)	2011-11-17	2013-07-11	Shalender Bhasin	Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en)	2012-03-29	2013-10-03	Genentech, Inc.	Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en)	2012-04-30	2013-11-07	Cell Signaling Technology, Inc.	Anti-hepatitis b virus antibodies and use thereof
EP2861617A1 (en)	2012-06-15	2015-04-22	Pfizer Inc.	Improved antagonist antibodies against gdf-8 and uses therefor
AU2013341353B2 (en)	2012-11-06	2017-03-16	Children's Medical Center Corporation	Compositions and methods for modulating cell signaling
WO2014178863A1 (en) *	2013-05-01	2014-11-06	Genzyme Corporation	Compositions and methods for treating spinal muscular atrophy
AU2014262843B2 (en)	2013-05-06	2017-06-22	Scholar Rock, Inc.	Compositions and methods for growth factor modulation
EP2853898B1 (en)	2013-09-27	2017-01-04	Medizinische Hochschule Hannover	Analysis of myostatin in serum
US10004814B2 (en)	2013-11-11	2018-06-26	Sirna Therapeutics, Inc.	Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015195094A1 (en) *	2014-06-17	2015-12-23	Ember Therapeutics, Inc.	Anti-activin and nati-myostatin antibodies and methods of using the same
EP3215175A4 (en) *	2014-11-06	2018-06-27	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073879A2 (en)	2014-11-06	2016-05-12	Scholar Rock, Inc.	Transforming growth factor-related antibodies and uses thereof
PE20221834A1 (es)	2014-12-19	2022-11-29	Chugai Pharmaceutical Co Ltd	Anticuerpos antimiostatina
EA201792298A1 (ru) *	2015-04-15	2018-04-30	Регенерон Фармасьютикалз, Инк.	Способы увеличения силы и функциональности с помощью ингибиторов gdf8
CA3036652A1 (en)	2015-09-15	2017-03-23	Scholar Rock, Inc.	Anti-pro/latent-myostatin antibodies and uses thereof
KR20180094110A (ko)	2016-01-08	2018-08-22	스칼러 락, 인크.	항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
JP6823167B2 (ja)	2016-06-13	2021-01-27	スカラーロックインコーポレイテッドＳｃｈｏｌａｒＲｏｃｋ，Ｉｎｃ．	ミオスタチン阻害剤の使用および併用療法
JOP20190152A1 (ar)	2016-12-21	2019-06-20	Novartis Ag	مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

2017
- 2017-06-13 JP JP2019517209A patent/JP6823167B2/ja active Active
- 2017-06-13 WO PCT/US2017/037332 patent/WO2017218592A1/en active Application Filing
- 2017-06-13 AU AU2017283546A patent/AU2017283546C1/en active Active
- 2017-06-13 ES ES17732001T patent/ES2830440T3/es active Active
- 2017-06-13 LT LTEP17732001.7T patent/LT3368069T/lt unknown
- 2017-06-13 IL IL301468A patent/IL301468A/en unknown
- 2017-06-13 KR KR1020237005734A patent/KR20230028813A/ko active Application Filing
- 2017-06-13 DK DK17732001.7T patent/DK3368069T3/da active
- 2017-06-13 KR KR1020197000822A patent/KR102271635B1/ko active IP Right Grant
- 2017-06-13 EP EP17732001.7A patent/EP3368069B1/en active Active
- 2017-06-13 EP EP20179533.3A patent/EP3785728A3/en active Pending
- 2017-06-13 HU HUE17732001A patent/HUE051480T2/hu unknown
- 2017-06-13 SI SI201730485T patent/SI3368069T1/sl unknown
- 2017-06-13 EP EP23157280.1A patent/EP4218804A3/en active Pending
- 2017-06-13 MY MYPI2018002494A patent/MY185614A/en unknown
- 2017-06-13 US US16/308,007 patent/US10946036B2/en active Active
- 2017-06-13 PE PE2018003207A patent/PE20190205A1/es unknown
- 2017-06-13 PT PT177320017T patent/PT3368069T/pt unknown
- 2017-06-13 RS RS20201327A patent/RS61090B1/sr unknown
- 2017-06-13 KR KR1020217019817A patent/KR20210082548A/ko not_active IP Right Cessation
- 2017-06-13 KR KR1020237042111A patent/KR20230169484A/ko active Application Filing
2018
- 2018-12-05 IL IL263510A patent/IL263510A/en unknown
- 2018-12-13 CL CL2018003588A patent/CL2018003588A1/es unknown
2020
- 2020-07-27 AU AU2020210134A patent/AU2020210134B2/en active Active
- 2020-10-30 HR HRP20201764TT patent/HRP20201764T1/hr unknown
- 2020-11-03 CY CY20201101038T patent/CY1123678T1/el unknown
2021
- 2021-01-05 JP JP2021000367A patent/JP7161554B2/ja active Active
- 2021-02-03 US US17/248,700 patent/US20210283166A1/en active Pending
- 2021-11-04 AU AU2021261907A patent/AU2021261907A1/en active Pending
2022
- 2022-04-08 JP JP2022064360A patent/JP7344337B2/ja active Active
2023
- 2023-09-01 JP JP2023142275A patent/JP2023164920A/ja active Pending

Also Published As

Publication number	Publication date
WO2017218592A1 (en)	2017-12-21
IL301468A (en)	2023-05-01
EP3785728A3 (en)	2021-04-28
EP3368069A1 (en)	2018-09-05
KR102271635B1 (ko)	2021-07-06
EP4218804A3 (en)	2023-09-13
JP2022101593A (ja)	2022-07-06
US10946036B2 (en)	2021-03-16
PE20190205A1 (es)	2019-02-07
LT3368069T (lt)	2020-12-10
HRP20201764T1 (hr)	2020-12-25
PT3368069T (pt)	2020-11-11
EP4218804A2 (en)	2023-08-02
AU2017283546A1 (en)	2018-12-20
SI3368069T1 (sl)	2021-03-31
CL2018003588A1 (es)	2019-03-01
EP3368069B1 (en)	2020-08-05
JP2023164920A (ja)	2023-11-14
HUE051480T2 (hu)	2021-03-01
KR20210082548A (ko)	2021-07-05
JP2019523295A (ja)	2019-08-22
JP2021063107A (ja)	2021-04-22
AU2020210134A1 (en)	2020-08-13
MY185614A (en)	2021-05-25
RS61090B1 (sr)	2020-12-31
AU2017283546C1 (en)	2020-11-19
US20210283166A1 (en)	2021-09-16
AU2020210134B2 (en)	2021-11-04
IL263510A (en)	2019-01-31
KR20230028813A (ko)	2023-03-02
JP6823167B2 (ja)	2021-01-27
CY1123678T1 (el)	2022-03-24
AU2021261907A1 (en)	2021-12-02
KR20230169484A (ko)	2023-12-15
JP7161554B2 (ja)	2022-10-26
US20190255093A1 (en)	2019-08-22
EP3785728A2 (en)	2021-03-03
ES2830440T3 (es)	2021-06-03
AU2017283546B2 (en)	2020-05-21
KR20190017933A (ko)	2019-02-20
JP7344337B2 (ja)	2023-09-13

Publication	Publication Date	Title
DK3368069T3 (da)	2020-11-02	Anvendelse af myostatininhibitorer og kombinationsterapier
ES2967536T3 (es)	2024-04-30	Inhibidores de Mnk y métodos relacionados con los mismos
HK1259232A1 (zh)	2019-11-29	Menin-mll的取代抑制劑及其使用方法
DK3678668T3 (da)	2024-04-08	ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3259253T3 (da)	2020-04-14	Sulfonylureaer og relaterede forbindelser og brug af samme
DK3653221T3 (da)	2022-10-24	Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3185868T3 (da)	2022-05-23	Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3234133T3 (da)	2021-02-08	Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3227310T3 (da)	2019-09-30	Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
DK3215532T3 (da)	2020-01-02	Anti-TIM3-antistoffer og fremgangsmåder til anvendelse
IL267291B (en)	2022-12-01	Actonucleotidase inhibitors and methods of using them
DK3377612T3 (da)	2021-12-13	Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3240785T3 (da)	2021-09-27	Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf
DK3160956T3 (da)	2020-08-31	Inhibitorer af lysin-specifik demethylase-1
DK3452485T3 (da)	2020-11-09	Arginasehæmmere og deres terapeutiske anvendelser
DK3350201T3 (da)	2022-03-07	Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3122359T3 (da)	2021-03-08	Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer
DK3511319T3 (da)	2023-07-31	Hæmmere af lysinspecifik demethylase-1
DK3288553T3 (da)	2023-01-23	Kombinationer af cannabinoider og n-acylethanolaminer
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3543240T3 (da)	2022-10-10	URAT1-inhibitor og anvendelse deraf
DK3394065T3 (da)	2021-05-31	Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3303339T3 (da)	2021-04-12	Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme